HOME
EDITORIAL: “On a treasure hunt”
SUPPORT THE R&D APPEAL
HOW YOU CAN HELP DNDi?
 
Target Product Profile: Starting with patients in mind
Lost in translation: What stops basic science from being translated into new drugs?
The Drug Discovery Process
DNDi's Discovery Projects
Meet Prof Jim McKerrow, Principal Investigator DNDi
DNDi's Intellectual Property Policy puts patients first
Patients before patents: Global calls for a generic drug to counter Avian Flu
Excellent results of AS/MQ trials in Thailand
Patient Representative for DNDi's Board
Kitasato Microbial Medal 2005
Nifurtimox-Eflornithine trials start in Isangi, DRC
Partnerships with Indian scientists
Successful launch of HAT platform in Kinshasa
Prof Alan Fairlamb:
A tireless advocate for neglected diseases
New report reveals paucity of government support to neglected disease drug R&D
European Parliament adopts important resolution on major and neglected diseases
New tropical disease research centre at Liverpool School of Tropical Medicine
More money for neglected diseases
 
DNDi' Discovery Projects
• Trypanothione reductase inhibitors (tryps, leish)
• Kitasato Screening (tryps, leish)
• CDRI Screening (tryps, leish)
• DHFR inhibitors (tryps, leish)

• Cysteine protease inhibitors (HAT)
• Nitroimidazoles (HAT & Chagas)
• Protein farnesyl-transferase inhibitors (HAT)
• Benzofuroxans (Chagas)
• Ascofuranone (HAT)
• Nitroheterocycles (HAT)

HAT: Human African trypanosomiasis
Leish: Leishmaniasis
Tryps: Trypanosomiasis
Chagas: South American trypanosomiasis

See also:
Target Product Profile: Starting with patients in mind
Lost in translation: What stops basic science from being translated into new drugs?
The Drug Discovery Process
Published by Drugs for Neglected Diseases Initiative - 1 Place St Gervais 1201 Geneva Switzerland
Editor: Jaya Banerji - Tel: +41 22 906 9230 - Fax: +41 22 906 9231 - www.dndi.org